Drug Res (Stuttg) 2021; 71(06): 312-316
DOI: 10.1055/a-1369-8867
Original Article

Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624

Tae Kon Kim
Funding: This work was supported by the Jungwon University Research Grant (2020–013)

Abstract

We developed unique small-molecule inhibitors of hepatitis C virus (HCV), which had potent activity for HCV entry inhibition and multi-genotypic antiviral activity. In this study, a sensitive and reliable method for the quantitation of JW5624 in rat plasma was developed and validated using high performance liquid chromatography. Chromatographic separation was achieved using a reversed-phase (C18) column. The mobile phase, 0.02 M ammonium acetate buffer:acetonitrile (30:70, v/v), was run at a flow rate of 1.0 mL/min, and the column eluent was monitored using an ultraviolet detector at 254 nm at room temperature. The retention times of sildenafil (an internal standard), and JW5624 were approximately 5.9 and 7.3 min, respectively. The detection limit of JW5624 in rat plasma was 0.03 μg/mL. Pharmacokinetic parameters of JW5624 was evaluated after intravenous (i. v.; at doses of 5 mg/kg) and oral (p.o.; at doses of 10 mg/kg) administration of JW5624 in rats. After p.o. administration (10 mg/kg) of JW5624, F value was approximately 71.0%. These results suggest that JW5624 can be a potential candidate drug for the development of HCV entry inhibitors.



Publication History

Received: 24 July 2020

Accepted: 11 January 2021

Article published online:
03 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81
  • 2 Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-938
  • 3 Van Regenmortel MH. Virus species and virus identification: Past and current controversies. Infect Genet Evol 2007; 7: 133-144
  • 4 Simmonds P, Bukh J, Combet C. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973
  • 5 ElHefnawi MM, Zada S, El-Azab IA. Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: A meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a. Virol J 2010; 7: 130
  • 6 Aghemo A, Degasperi E, Colombo M. Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials. Dig Liver Dis 2013; 45: 1-7
  • 7 Hofmann WP, Chung TL, Osbahr C. et al. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-alpha and the protease inhibitors boceprevir or telaprevir. Antivir Ther 2011; 16: 695-704
  • 8 Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681
  • 9 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation /Guidances/ucm070107.pdf
  • 10 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1009-1095
  • 11 Choi YH, Kim SG, Lee MG. Dose-independent pharmacokinetics metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci 2006; 95: 2543-2552